BioNTech SE SEC filings BNTX
BioNTech SE has 589 filings in SEC EDGAR's recent list, going back to Jun 19, 2019. Its latest annual report, Form 20-F, was filed on Mar 10, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SC TO-T/A | Filing | Dec 18, 2025 | — |
| SC TO-T/A | Filing | Dec 3, 2025 | — |
| 425 | Filing | Dec 3, 2025 | — |
| SC TO-T/A | Filing | Nov 26, 2025 | — |
| 425 | Filing | Nov 26, 2025 | — |
| 425 | Filing | Nov 12, 2025 | — |
| 425 | Filing | Nov 12, 2025 | — |
| SC TO-T/A | Filing | Oct 22, 2025 | — |
| 425 | Filing | Oct 22, 2025 | — |
| 425 | Filing | Oct 22, 2025 | — |
| SC TO-T | Filing | Oct 21, 2025 | — |
| 425 | Filing | Oct 20, 2025 | — |
| 425 | Filing | Oct 20, 2025 | — |
| CORRESP | Letter to the SEC | Sep 8, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2025 | — |
| CORRESP | Letter to the SEC | Aug 11, 2025 | — |
| 425 | Filing | Aug 11, 2025 | — |
| 425 | Filing | Aug 8, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2025 | — |
| DRSLTR | Filing | Jun 30, 2025 | — |
| DRS | Filing | Jun 30, 2025 | — |
| 425 | Filing | Jun 17, 2025 | — |
| 425 | Filing | Jun 12, 2025 | — |
| 425 | Filing | Jun 12, 2025 | — |
| 425 | Filing | Jun 12, 2025 | — |
| 425 | Filing | Jun 12, 2025 | — |
| 425 | Filing | Jun 12, 2025 | — |
| D | Filing | Apr 14, 2022 | — |
| D | Filing | Sep 17, 2020 | — |
| EFFECT | Filing | Jul 24, 2020 | — |
| EFFECT | Filing | Jul 22, 2020 | — |
| DRS | Filing | Jun 15, 2020 | — |
| DRS | Filing | Jun 12, 2020 | — |
| EFFECT | Filing | Apr 2, 2020 | — |
| CORRESP | Letter to the SEC | Mar 31, 2020 | — |
| 425 | Filing | Mar 31, 2020 | — |
| 425 | Filing | Mar 31, 2020 | — |
| 425 | Filing | Mar 31, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2020 | — |
| DRSLTR | Filing | Feb 20, 2020 | — |
| DRS | Filing | Feb 20, 2020 | — |
| RW | Filing | Feb 7, 2020 | — |
| EFFECT | Filing | Feb 5, 2020 | — |
| CORRESP | Letter to the SEC | Feb 3, 2020 | — |
| CORRESP | Letter to the SEC | Feb 3, 2020 | — |
| SEC STAFF LETTER | Filing | Jan 29, 2020 | — |
| SEC STAFF LETTER | Filing | Jan 29, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2020 | — |
| DRS | Filing | Jan 27, 2020 | — |
| 425 | Filing | Jan 23, 2020 | — |
| 425 | Filing | Jan 16, 2020 | — |
| 425 | Filing | Jan 16, 2020 | — |
| EFFECT | Filing | Oct 9, 2019 | — |
| CERT | Filing | Oct 9, 2019 | — |
| CORRESP | Letter to the SEC | Oct 7, 2019 | — |
| CORRESP | Letter to the SEC | Oct 7, 2019 | — |
| 8-A12B | Filing | Oct 7, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 30, 2019 | — |
| CORRESP | Letter to the SEC | Sep 24, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2019 | — |
| CORRESP | Letter to the SEC | Sep 19, 2019 | — |
| CORRESP | Letter to the SEC | Sep 9, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2019 | — |
| DRSLTR | Filing | Aug 5, 2019 | — |
| DRS/A | Filing | Aug 5, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2019 | — |
| SEC STAFF LETTER | Filing | Jul 10, 2019 | — |
| DRS | Filing | Jun 19, 2019 | — |
Showing 68 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BNTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Germany
- Headquarters
- Mainz, Germany
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1776985
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.